Mark Geyer

Mark Geyer

Professor of Psychiatry and Neurosciences Emeritus at the University of California San Diego (UCSD)

Mark A. Geyer Ph.D. is Distinguished Professor of Psychiatry and Neurosciences Emeritus at the University of California San Diego (UCSD) and directs the Neuropsychopharmacology Unit of the VISN 22 Veterans Administration Mental Illness Research, Clinical, and Education Center. Since receiving his doctorate in Psychology in 1972, he has focused on basic research addressing psychotic disorders and the related behavioral and neurobiological effects of psychedelics and other psychoactive drugs. For four decades, his group has had continuous funding from the National Institute on Drug Abuse to study the behavioral effects of psychedelics and entactogens. At UCSD, he is a founding member of the Consortium for Translational Research in Neuropsychopharmacology (CTRIN) and Translational Research in Psychophysiology, Exploration, and Cognition (TRIPEC) groups. In 1993, he co-founded the Heffter Research Institute, which pioneered and supported much of the scientific research that has prompted the exploration of psychedelics as potential therapeutics in humans. He has recently co-founded the Psychedelics and Health Research Initiative at UCSD, which is exploring the efficacy of psychedelics in the treatment of pain disorders. Dr. Geyer is respected internationally for his research on the psychophysiology, neurobiology, and pharmacotherapy of schizophrenia and bipolar disorder. He has published 470+ peer-reviewed papers and 50+ reviews, including many addressing the mechanisms subserving the effects of antipsychotics, psychostimulants, psychedelics, and entactogens. He is the lead Series Editor for Current Topics in Behavioral Neurosciences, which has completed 43+ volumes. He was involved intensively in the NIMH-funded MATRICS, TURNS, and CNTRICS Programs and has served as a receiving Editor of Neuropsychopharmacology, Neuropharmacology, Psychopharmacology, and Schizophrenia Bulletin, and as Scientific Advisor to European Union’s Innovative Medicine Initiative. He is a Fellow of AAAS, American College of Neuropsychopharmacology (ACNP), and American Psychological Society, Past-President of the International Society for Serotonin Research and the International Behavioral Neuroscience Society, member of Scientific Council of the Brain and Behavior Research Foundation (aka NARSAD), 2011 awardee of Bleuler Prize for Research in the Schizophrenias, and the 2014 Julius Axelrod Mentorship Awardee from ACNP. Dr. Geyer’s broad experience as a researcher, grant reviewer, journal editor, and teacher lends invaluable scientific and professional expertise to several organizations, as he provides leadership to develop strong programs in the behavioral psychopharmacology and clinical applications of psychoactive agents.

"At Eleusis, one realises, if never before, that there is no salvation in becoming adapted to a world which is crazy. At Eleusis, one becomes adapted to the cosmos. Outwardly Eleusis may seem broken, disintegrated with the crumbled past; actually, Eleusis is still intact and it is we who are broken, dispersed, crumbling to dust. Eleusis lives; lives eternally in the midst of a dying world."
Henry Miller

To stay in touch with the World Human Forum, contact us here